Shiga Progression of Diabetes, Nephropathy and Retinopathy

Summary

The purpose of this study is to investigate whether the oral anti-diabetic drug, Thiazolidine (TZD) is effective in suppression of onset or progressin of diabetic nephropathy in Japanese type 2 diabetic patients.

Conditions

• Type 2 Diabetes Mellitus

Interventions

DRUG

Pioglitazone add on to SU or biguanide

As an initial dosing, 15mg/day of pioglitazone is administered to the patients for 2 years, who are taking SU or biguanide.

DRUG

SU or Biguanide

As an initial dose,a common dose of SU or biguanide is administered to the patients for 2 years.

Sponsors & Collaborators

• Kanazawa Medical University

  collaborator OTHER

• Nagahama Red Cross Hospital

  collaborator OTHER

• Nagahama City Hospital

  collaborator OTHER

• Kohka Public Hospital

  collaborator UNKNOWN

• Second Okamoto General Hospital

  collaborator UNKNOWN

• Omihachiman COmmunity Medical Center

  collaborator UNKNOWN

• Yasu Hospital

  collaborator UNKNOWN

• Toyosato Hospital

  collaborator UNKNOWN

• Ako City Hospital

  collaborator OTHER

• Horide Clinic

  collaborator UNKNOWN

• Kawabata Clinic

  collaborator UNKNOWN

• Seta Clinic

  collaborator UNKNOWN

• Shiga Clinic

  collaborator UNKNOWN

• Osaka University

  collaborator OTHER

• NTT West Osaka Hospital

  collaborator UNKNOWN

• Hyogo prefectural Amagasaki Hospital

  collaborator UNKNOWN

• Tomita Clinic

  collaborator UNKNOWN

• Sawada Clinic

  collaborator UNKNOWN

• Social Insurance Shiga Hospital

  collaborator UNKNOWN

• Shiga University

  lead OTHER

Principal Investigators

• Atsunori Kashiwagi, PhD. · Tsukiwa-machi, Seta, Otsu, Shiga, Japan

Study Design

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

NONE

Model

PARALLEL

Eligibility

Min Age

20 Years

Max Age

75 Years

Sex

ALL

Healthy Volunteers

No

Timeline & Regulatory

Start

2008-03-31

Primary Completion

2011-11-30

Completion

2011-11-30

Countries

• Japan

Study Locations